Previously unrecognized genetic structural variants in childhood leukemias could be used to evaluate the presence of minimal residual disease during chemotherapy and help to determine response to various therapies.
Tracking large numbers of individualized tumor mutations in cell-free DNA improved minimal residual disease detection in breast cancer patients, though the sensitivity is driven by the number of mutations available to track.
The FDA granted fast track designation to balstilimab and zalifrelimab based on comprehensive data found to support their potential as a combination therapy.
Given these findings, researchers highlighted the need for interventions and policy efforts that address reducing food insecurity and financial worry among cancer survivors.
Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes.
The associate professor of hematology spoke with CancerNetwork®about frontline treatments available for patients with chronic lymphocytic leukemia and the toxicities present for these treatments.
An international systematic review and meta-analysis indicated that stereotactic body radiation therapy compared to conventionally fractioned radiation therapy with concurrent chemotherapy may offer a modest improvement in OS with a more favorable toxicity profile.
The FDA granted orphan drug designation to umbralisib based on results from the phase IIb UNITY-NHL trial cohort of patients with follicular lymphoma who have received at least 2 prior lines of therapy, including an anti-CD20 monoclonal antibody and an alkylating agent.
After a serious adverse reaction to a clinical trial put her in critical condition, Barbara Bigelow now shows no signs of breast cancer and is no longer on any cancer medications.
The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.